Given the commencement of CDH17 trials was delayed due to regulatory processes, its likely the news is considered significant to the industry. After clearing the FDA’s IND application in late 2023, the company announced that the phase 1/2 trial would now start patient enrollment in 2024.
The other thing to remember is that UPenn is widely recognized as the birthplace of CAR-T therapy. Their groundbreaking work led to the first FDA-approved CAR-T cell therapy, Kymriah, for treating certain types of leukemia. This innovation has since opened the door to various CAR-T therapies targeting different cancers.
CDH17 CAR-T is classed as 3rd-gen technology and its finally in the clinic at UPenn (among other US sites). Its newsworthy, don't you think?
CHM Price at posting:
1.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)